MEI Pharma Inc. [NASDAQ: MEIP] gained 1.70% or 0.0 points to close at $0.38 with a heavy trading volume of 498471 shares. The company report on November 18, 2022 that Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
– Interim data from Phase II Study of Zandelisib shows 75.4% ORR in Japanese patients with Indolent B-cell NHL -.
– Publication of results from additional Phase 1 study now available in International Journal of Hematology -.
It opened the trading session at $0.3733, the shares rose to $0.395 and dropped to $0.3728, the range by which the price of stock traded the whole day. The daily chart for MEIP points out that the company has recorded -8.20% loss over the past six months. However, it is still -35.71% lower than its most recent low trading price.
If we look at the average trading volume of 750.77K shares, MEIP reached to a volume of 498471 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about MEI Pharma Inc. [MEIP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MEIP shares is $5.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MEIP stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for MEI Pharma Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on March 25, 2022. While these analysts kept the previous recommendation, Stifel dropped their target price from $6 to $2. The new note on the price target was released on March 25, 2022, representing the official price target for MEI Pharma Inc. stock. Previously, the target price had yet another drop from $4 to $1, while Jefferies kept a Hold rating on MEIP stock.
The Average True Range (ATR) for MEI Pharma Inc. is set at 0.03, with the Price to Sales ratio for MEIP stock in the period of the last 12 months amounting to 1.26. The Price to Book ratio for the last quarter was 1.37, with the Price to Cash per share for the same quarter was set at 1.01.
Trading performance analysis for MEIP stock
MEI Pharma Inc. [MEIP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 6.33. With this latest performance, MEIP shares gained by 12.62% in over the last four-week period, additionally sinking by -8.20% over the last 6 months – not to mention a drop of -86.03% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MEIP stock in for the last two-week period is set at 56.66, with the RSI for the last a single of trading hit 61.94, and the three-weeks RSI is set at 52.17 for MEI Pharma Inc. [MEIP]. The present Moving Average for the last 50 days of trading for this stock 0.3755, while it was recorded at 0.3855 for the last single week of trading, and 0.7198 for the last 200 days.
MEI Pharma Inc. [MEIP]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and MEI Pharma Inc. [MEIP] shares currently have an operating margin of -185.48 and a Gross Margin at +96.97. MEI Pharma Inc.’s Net Margin is presently recorded at -133.80.
Return on Equity for this stock declined to -116.14, with Return on Assets sitting at -30.95.
MEI Pharma Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.40 and a Current Ratio set at 6.40.
MEI Pharma Inc. [MEIP]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MEIP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for MEI Pharma Inc. go to -0.10%.
An analysis of insider ownership at MEI Pharma Inc. [MEIP]
There are presently around $18 million, or 38.10% of MEIP stock, in the hands of institutional investors. The top three institutional holders of MEIP stocks are: NEA MANAGEMENT COMPANY, LLC with ownership of 8,533,072, which is approximately 0% of the company’s market cap and around 0.48% of the total institutional ownership; VANGUARD GROUP INC, holding 7,668,708 shares of the stock with an approximate value of $2.94 million in MEIP stocks shares; and ANSON FUNDS MANAGEMENT LP, currently with $1.77 million in MEIP stock with ownership of nearly 0% of the company’s market capitalization.
Positions in MEI Pharma Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 28 institutional holders increased their position in MEI Pharma Inc. [NASDAQ:MEIP] by around 2,297,706 shares. Additionally, 32 investors decreased positions by around 2,010,276 shares, while 19 investors held positions by with 43,498,726 shares. The mentioned changes placed institutional holdings at 47,806,708 shares, according to the latest SEC report filing. MEIP stock had 13 new institutional investments in for a total of 556,357 shares, while 13 institutional investors sold positions of 816,573 shares during the same period.